2026 Q1 -tulosraportti
Vain PDF
71 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 9.6. | ||
2026 Q1 -tulosraportti 11.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·16.7.A lot of headwinds here….
A bit from chat-gpt, if one cares to read it: 1. The biggest news: The FDA process is now officially underway Intellia has announced that they have initiated a "rolling BLA" (Biologics License Application) with the FDA for lonvo-z for the treatment of hereditary angioedema (HAE). Intellia Therapeutics + 1 This is important because: The FDA has accepted that the application can be submitted on a rolling basis. This is because the treatment has received RMAT status (Regenerative Medicine Advanced Therapy), which can accelerate the review process. Intellia Therapeutics This is a step we have previously talked about, but now the process is actually underway. 🟢 2. The launch plan is maintained The company maintains the goal of: to complete the BLA submission in H2 2026 with a potential US launch in H1 2027, if the FDA approves the treatment. GlobeNewswire This tells me that management does not see the latest Phase 3 data as an obstacle to the approval process. 🟢 3. Good news about nex-z (ATTR) This is actually also positive in relation to something we have followed closely for many months: Both MAGNITUDE Phase 3 studies have now resumed. This means that: The FDA has lifted the clinical hold for both ATTR-PN and ATTR-CM. Patient screening has resumed. Intellia still expects to recruit patients for the studies. Reuters + 1 I know how much we have previously followed the clinical hold case, and in my assessment, it is one of the most important fundamental improvements in the case. 🟡 4. Why is the stock still falling then? That is probably the most frustrating thing. Even though the news is good, the market still seems concerned about: how quickly lonvo-z will be adopted, how large the market share will be, and the long-term safety data for permanent gene editing. That is why the stock is not yet valued as a "finished" commercial success. 🔴 Has there been any new bad news? No – not as far as I can see. I have not found: new safety issues, new deaths, new FDA interventions, new clinical holds, or major analyst downgrades. Intellia Therapeutics + 1 My assessment If I compare the situation with a few months ago, I actually think the case has become stronger: A few months ago Now Clinical hold on nex-z ✅ Lifted Uncertainty about HAE Phase 3 ✅ Positive Phase 3 data Financing uncertain ✅ Issuance completed FDA application was future ✅ Rolling BLA has started That is why I continue to believe that the fundamental development has been better than the share price development.
·5.7.Is there any news coming? Or what are your thoughts on this stock, is there potential in the coming years?So, they have applied to the FDA for permission to go into production and enter the market in the USA. I think the stock will rise when they actually start generating revenue and take market share from the current treatments for angioedema. I also expect a price increase, in line with positive data from their second trial. The risk is, of course, bad data from, or negative feedback from the FDA. Institutional investors like ARK invest and Blackrock have not sold any of their shares. ARK, on the other hand, has increased their holdings recently, which I also think is a good sign. BIO-TECH is volatile, so expect a rollercoaster no matter what.- 4.6.Its happening 🚀
Interesting this, yes. No capital requirement for the next 1.5 years, without counting in profit from lonvo-z. 
·29.4.What do you think? In -or out?The current drop is due to a new issue at 10.75 USD, as Illuminati writes. It is very normal for biotech to make new issues after good data, and you typically see the price quickly adjust to the issue price. Since we were down and trading around that level yesterday, I believe we will see a steady increase in the coming time, while we await approval from FDA etc. to go into production. I am not pulling out, unless bad data comes out, and currently have an order at price 11, if we get down there again. PT, the case has moved away from hype - a large part of uncertainty has disappeared, so we have gone from being a lottery ticket to having a real product. Expect new price targets from analysts at around 25-30 USD, with the caveat that they may rise/fall in line with new data in the coming year. Institutional investors are still digesting data from this round, but since it seems that the bigger funds have all taken positions, one must assume it is only panic selling and paper hands that have sold out. If you believed in the company when you bought in, you should stay now - after all, they have proven that they can succeed with the treatment and technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
71 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·16.7.A lot of headwinds here….A bit from chat-gpt, if one cares to read it: 1. The biggest news: The FDA process is now officially underway Intellia has announced that they have initiated a "rolling BLA" (Biologics License Application) with the FDA for lonvo-z for the treatment of hereditary angioedema (HAE). Intellia Therapeutics + 1 This is important because: The FDA has accepted that the application can be submitted on a rolling basis. This is because the treatment has received RMAT status (Regenerative Medicine Advanced Therapy), which can accelerate the review process. Intellia Therapeutics This is a step we have previously talked about, but now the process is actually underway. 🟢 2. The launch plan is maintained The company maintains the goal of: to complete the BLA submission in H2 2026 with a potential US launch in H1 2027, if the FDA approves the treatment. GlobeNewswire This tells me that management does not see the latest Phase 3 data as an obstacle to the approval process. 🟢 3. Good news about nex-z (ATTR) This is actually also positive in relation to something we have followed closely for many months: Both MAGNITUDE Phase 3 studies have now resumed. This means that: The FDA has lifted the clinical hold for both ATTR-PN and ATTR-CM. Patient screening has resumed. Intellia still expects to recruit patients for the studies. Reuters + 1 I know how much we have previously followed the clinical hold case, and in my assessment, it is one of the most important fundamental improvements in the case. 🟡 4. Why is the stock still falling then? That is probably the most frustrating thing. Even though the news is good, the market still seems concerned about: how quickly lonvo-z will be adopted, how large the market share will be, and the long-term safety data for permanent gene editing. That is why the stock is not yet valued as a "finished" commercial success. 🔴 Has there been any new bad news? No – not as far as I can see. I have not found: new safety issues, new deaths, new FDA interventions, new clinical holds, or major analyst downgrades. Intellia Therapeutics + 1 My assessment If I compare the situation with a few months ago, I actually think the case has become stronger: A few months ago Now Clinical hold on nex-z ✅ Lifted Uncertainty about HAE Phase 3 ✅ Positive Phase 3 data Financing uncertain ✅ Issuance completed FDA application was future ✅ Rolling BLA has started That is why I continue to believe that the fundamental development has been better than the share price development.
- ·5.7.Is there any news coming? Or what are your thoughts on this stock, is there potential in the coming years?So, they have applied to the FDA for permission to go into production and enter the market in the USA. I think the stock will rise when they actually start generating revenue and take market share from the current treatments for angioedema. I also expect a price increase, in line with positive data from their second trial. The risk is, of course, bad data from, or negative feedback from the FDA. Institutional investors like ARK invest and Blackrock have not sold any of their shares. ARK, on the other hand, has increased their holdings recently, which I also think is a good sign. BIO-TECH is volatile, so expect a rollercoaster no matter what.
- 4.6.Its happening 🚀Interesting this, yes. No capital requirement for the next 1.5 years, without counting in profit from lonvo-z.
- ·29.4.What do you think? In -or out?The current drop is due to a new issue at 10.75 USD, as Illuminati writes. It is very normal for biotech to make new issues after good data, and you typically see the price quickly adjust to the issue price. Since we were down and trading around that level yesterday, I believe we will see a steady increase in the coming time, while we await approval from FDA etc. to go into production. I am not pulling out, unless bad data comes out, and currently have an order at price 11, if we get down there again. PT, the case has moved away from hype - a large part of uncertainty has disappeared, so we have gone from being a lottery ticket to having a real product. Expect new price targets from analysts at around 25-30 USD, with the caveat that they may rise/fall in line with new data in the coming year. Institutional investors are still digesting data from this round, but since it seems that the bigger funds have all taken positions, one must assume it is only panic selling and paper hands that have sold out. If you believed in the company when you bought in, you should stay now - after all, they have proven that they can succeed with the treatment and technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 9.6. | ||
2026 Q1 -tulosraportti 11.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 |
2026 Q1 -tulosraportti
Vain PDF
71 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 9.6. | ||
2026 Q1 -tulosraportti 11.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·16.7.A lot of headwinds here….A bit from chat-gpt, if one cares to read it: 1. The biggest news: The FDA process is now officially underway Intellia has announced that they have initiated a "rolling BLA" (Biologics License Application) with the FDA for lonvo-z for the treatment of hereditary angioedema (HAE). Intellia Therapeutics + 1 This is important because: The FDA has accepted that the application can be submitted on a rolling basis. This is because the treatment has received RMAT status (Regenerative Medicine Advanced Therapy), which can accelerate the review process. Intellia Therapeutics This is a step we have previously talked about, but now the process is actually underway. 🟢 2. The launch plan is maintained The company maintains the goal of: to complete the BLA submission in H2 2026 with a potential US launch in H1 2027, if the FDA approves the treatment. GlobeNewswire This tells me that management does not see the latest Phase 3 data as an obstacle to the approval process. 🟢 3. Good news about nex-z (ATTR) This is actually also positive in relation to something we have followed closely for many months: Both MAGNITUDE Phase 3 studies have now resumed. This means that: The FDA has lifted the clinical hold for both ATTR-PN and ATTR-CM. Patient screening has resumed. Intellia still expects to recruit patients for the studies. Reuters + 1 I know how much we have previously followed the clinical hold case, and in my assessment, it is one of the most important fundamental improvements in the case. 🟡 4. Why is the stock still falling then? That is probably the most frustrating thing. Even though the news is good, the market still seems concerned about: how quickly lonvo-z will be adopted, how large the market share will be, and the long-term safety data for permanent gene editing. That is why the stock is not yet valued as a "finished" commercial success. 🔴 Has there been any new bad news? No – not as far as I can see. I have not found: new safety issues, new deaths, new FDA interventions, new clinical holds, or major analyst downgrades. Intellia Therapeutics + 1 My assessment If I compare the situation with a few months ago, I actually think the case has become stronger: A few months ago Now Clinical hold on nex-z ✅ Lifted Uncertainty about HAE Phase 3 ✅ Positive Phase 3 data Financing uncertain ✅ Issuance completed FDA application was future ✅ Rolling BLA has started That is why I continue to believe that the fundamental development has been better than the share price development.
- ·5.7.Is there any news coming? Or what are your thoughts on this stock, is there potential in the coming years?So, they have applied to the FDA for permission to go into production and enter the market in the USA. I think the stock will rise when they actually start generating revenue and take market share from the current treatments for angioedema. I also expect a price increase, in line with positive data from their second trial. The risk is, of course, bad data from, or negative feedback from the FDA. Institutional investors like ARK invest and Blackrock have not sold any of their shares. ARK, on the other hand, has increased their holdings recently, which I also think is a good sign. BIO-TECH is volatile, so expect a rollercoaster no matter what.
- 4.6.Its happening 🚀Interesting this, yes. No capital requirement for the next 1.5 years, without counting in profit from lonvo-z.
- ·29.4.What do you think? In -or out?The current drop is due to a new issue at 10.75 USD, as Illuminati writes. It is very normal for biotech to make new issues after good data, and you typically see the price quickly adjust to the issue price. Since we were down and trading around that level yesterday, I believe we will see a steady increase in the coming time, while we await approval from FDA etc. to go into production. I am not pulling out, unless bad data comes out, and currently have an order at price 11, if we get down there again. PT, the case has moved away from hype - a large part of uncertainty has disappeared, so we have gone from being a lottery ticket to having a real product. Expect new price targets from analysts at around 25-30 USD, with the caveat that they may rise/fall in line with new data in the coming year. Institutional investors are still digesting data from this round, but since it seems that the bigger funds have all taken positions, one must assume it is only panic selling and paper hands that have sold out. If you believed in the company when you bought in, you should stay now - after all, they have proven that they can succeed with the treatment and technology.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt